Evidence map›Paper›PMID 38181429›Full record

ArticleCardiovascular research2024

The role of cellular senescence in profibrillatory atrial remodelling associated with cardiac pathology.

Mozhdeh Mehdizadeh, Patrice Naud, Issam H Abu-Taha, Roddy Hiram, Feng Xiong, Jiening Xiao, Arnela Saljic, Markus Kamler, Nhung Vuong-Robillard, Eric Thorin and 6 more

Open access · bronzeAbstract read
In one paragraph

Article in Cardiovascular research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 1 pooled it
7.5field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 1 synthesis or guideline pooled it, 23 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Multicellular senescence programs in the aged heart.Journal of molecular and cellular cardiology plus · 2026
    Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Cellular and molecular mechanisms underlying cardiovascular aging.Cellular & molecular biology letters · 2025
    Review
  10. Article
  11. Review
  12. Review
  13. Article
  14. Review
  15. Review
  16. Article
  17. Animal and cellular models of atrial fibrillation: a review.Frontiers in cardiovascular medicine · 2025
    Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors at 6 institutions in 5 countries.

Mozhdeh MehdizadehResearch Center, Montreal Heart Institute, Université de Montréal, 5000 Belanger Street, Montreal, Quebec H1T 1C8, Canada.
Patrice NaudResearch Center, Montreal Heart Institute, Université de Montréal, 5000 Belanger Street, Montreal, Quebec H1T 1C8, Canada.
Issam H Abu-TahaInstitute of Pharmacology, West German Heart and Vascular Center, University Duisburg-Essen, Hufelandstrasse 55, Essen 45122, Germany.
Roddy HiramResearch Center, Montreal Heart Institute, Université de Montréal, 5000 Belanger Street, Montreal, Quebec H1T 1C8, Canada.
Feng XiongResearch Center, Montreal Heart Institute, Université de Montréal, 5000 Belanger Street, Montreal, Quebec H1T 1C8, Canada.
Jiening XiaoResearch Center, Montreal Heart Institute, Université de Montréal, 5000 Belanger Street, Montreal, Quebec H1T 1C8, Canada.
Arnela SaljicInstitute of Pharmacology, West German Heart and Vascular Center, University Duisburg-Essen, Hufelandstrasse 55, Essen 45122, Germany.ORCID 0000-0001-8910-0902
Markus KamlerDepartment of Thoracic and Cardiovascular Surgery, West German Heart and Vascular Center Essen, University Hospital Essen, Hufelandstrasse 55, Essen 45122, Germany.
Nhung Vuong-RobillardDepartment of Biochemistry, Université de Montréal, CRCHUM, 900 Saint Denis St, Montreal, Quebec H2X 0A9, Canada.
Eric ThorinResearch Center, Montreal Heart Institute, Université de Montréal, 5000 Belanger Street, Montreal, Quebec H1T 1C8, Canada.ORCID 0000-0001-5827-8935
Gerardo FerbeyreDepartment of Biochemistry, Université de Montréal, CRCHUM, 900 Saint Denis St, Montreal, Quebec H2X 0A9, Canada.ORCID 0000-0002-2146-618X
Jean-Claude TardifResearch Center, Montreal Heart Institute, Université de Montréal, 5000 Belanger Street, Montreal, Quebec H1T 1C8, Canada.ORCID 0000-0002-8200-8983
Martin G SiroisResearch Center, Montreal Heart Institute, Université de Montréal, 5000 Belanger Street, Montreal, Quebec H1T 1C8, Canada.
Jean Francois TanguayResearch Center, Montreal Heart Institute, Université de Montréal, 5000 Belanger Street, Montreal, Quebec H1T 1C8, Canada.
Dobromir DobrevResearch Center, Montreal Heart Institute, Université de Montréal, 5000 Belanger Street, Montreal, Quebec H1T 1C8, Canada.ORCID 0000-0002-4612-117X
Stanley NattelResearch Center, Montreal Heart Institute, Université de Montréal, 5000 Belanger Street, Montreal, Quebec H1T 1C8, Canada.ORCID 0000-0002-5565-3311
Montreal Heart Institute · CAUniversité de Montréal · CABaylor College of Medicine · USEssen University Hospital · DEUniversity of Copenhagen · DKWest German Heart and Vascular Center Essen · DE

Funding

Ryanodine receptor regulation in post-operative atrial fibrillationR01HL089598 · NHLBI · BAYLOR COLLEGE OF MEDICINE · PI WEHRENS, XANDER H.T. · 2007 to 2022
$6.5M
The Role of Inflammasome in the Pathogenesis of Atrial FibrillationR01HL136389 · NHLBI · BAYLOR COLLEGE OF MEDICINE · PI Na Li · 2017 to 2026
$5.6M
Sex-specific arrhythmogenic mechanisms of atrial fibrillationR01HL131517 · NHLBI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI Eleonora Grandi · 2016 to 2026
$5.0M
Resolution of inflammation and atrial fibrillationR01HL165704 · NHLBI · UNIVERSITY OF MINNESOTA · PI SAMUEL C DUDLEY · 2023 to 2026
$2.9M
Cardiac fibroblast inflammasome and atrial myopathyR01HL163277 · NHLBI · BAYLOR COLLEGE OF MEDICINE · PI LI, NA · 2022 to 2025
$2.8M
Role of Nucleoside-Diphosphate Kinase Signaling in Atrial FibrillationR01HL160992 · NHLBI · BAYLOR COLLEGE OF MEDICINE · PI Xander H.T. Wehrens · 2023 to 2026
$2.1M
FKBP5 AND CARDIAC ARRHYTHMOGENESISR01HL164838 · NHLBI · BAYLOR COLLEGE OF MEDICINE · PI Na Li · 2024 to 2026
$1.7M
Red Blood Cell Fatty Acid Biomarkers and Cardiovascular Disease RiskR01HL089590 · NHLBI · SANFORD RESEARCH/USD · PI HARRIS, WILLIAM S · 2008 to 2011
$683k
CIHR 148401NHLBI NIH HHS R01 HL089590NHLBI NIH HHS R01 HL089598NHLBI NIH HHS R01 HL131517NHLBI NIH HHS R01 HL136389NHLBI NIH HHS R01 HL160992NHLBI NIH HHS R01 HL163277NHLBI NIH HHS R01 HL164838NHLBI NIH HHS R01 HL165704NIH HHS R01-HL131517
6 · The paper itself

Abstract

aimsCellular senescence is a stress-related or aging response believed to contribute to many cardiac conditions; however, its role in atrial fibrillation (AF) is unknown. Age is the single most important determinant of the risk of AF. The present study was designed to (i) evaluate AF susceptibility and senescence marker expression in rat models of aging and myocardial infarction (MI), (ii) study the effect of reducing senescent-cell burden with senolytic therapy on the atrial substrate in MI rats, and (iii) assess senescence markers in human atrial tissue as a function of age and the presence of AF. METHODS AND

resultsAF susceptibility was studied with programmed electrical stimulation. Gene and protein expression was evaluated by immunoblot or immunofluorescence (protein) and digital polymerase chain reaction (PCR) or reverse transcriptase quantitative PCR (messenger RNA). A previously validated senolytic combination, dasatinib and quercetin, (D+Q; or corresponding vehicle) was administered from the time of sham or MI surgery through 28 days later. Experiments were performed blinded to treatment assignment. Burst pacing-induced AF was seen in 100% of aged (18-month old) rats, 87.5% of young MI rats, and 10% of young control (3-month old) rats (P ≤ 0.001 vs. each). Conduction velocity was slower in aged [both left atrium (LA) and right atrium (RA)] and young MI (LA) rats vs. young control rats (P ≤ 0.001 vs. each). Atrial fibrosis was greater in aged (LA and RA) and young MI (LA) vs. young control rats (P < 0.05 for each). Senolytic therapy reduced AF inducibility in MI rats (from 8/9 rats, 89% in MI vehicle, to 0/9 rats, 0% in MI D + Q, P < 0.001) and attenuated LA fibrosis. Double staining suggested that D + Q acts by clearing senescent myofibroblasts and endothelial cells. In human atria, senescence markers were upregulated in older (≥70 years) and long-standing AF patients vs. individuals ≤60 and sinus rhythm controls, respectively.

conclusionOur results point to a potentially significant role of cellular senescence in AF pathophysiology. Modulating cell senescence might provide a basis for novel therapeutic approaches to AF.

Indexed as

Atrial FibrillationAtrial RemodelingCellular SenescenceDisease Models, AnimalFibrosisHeart AtriaMyocardial InfarctionAgedAge FactorsAnimalsCardiac Pacing, ArtificialFemaleHumansMaleMiddle AgedQuercetinQuercetinSenotherapeuticsAF susceptibilityCellular senescenceFibrosisMyocardial infarctionSenolytic drugs

Identifiers

PMID38181429
PMCPMC11060482
OpenAlexW4390605911

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.